

Curriculum Vitae

Date Prepared: August 2, 2022
Name: Michael S. Sinha, M.D., J.D., M.P.H.
Office Address: Saint Louis University School of Law
 Center for Health Law Studies
 100 N. Tucker Boulevard, Room 936
 Saint Louis, MO 63101
Work E-mail: michael.sinha@slu.edu
Website: <https://www.slu.edu/law/faculty/michael-sinha.php>
Place of Birth: Saint Louis, MO

Education

2015	M.P.H.	Law and Public Health	Harvard T.H. Chan School of Public Health, Boston, MA
2012	J.D. (<i>cum laude</i>)	Law	SIU School of Law, Carbondale, IL
2012	M.D.	Medicine	Southern Illinois University (SIU) School of Medicine, Springfield, IL
2003	B.A. (<i>cum laude</i>)	Biophysical Chemistry (Honors)	Dartmouth College, Hanover, NH

Postdoctoral Training

2018-2021	Regulatory Science Fellow	Harvard-MIT Center for Regulatory Science (HMCRS)	Harvard Program in Therapeutic Science (HiTS), Harvard Medical School, Boston, MA
2016-2018	Postdoctoral Fellow	Pharmaceutical Law and Health Services Research	Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Y qo gpau'J qu kcn "Dquqp."O C

2022	Assistant Professor	Center for Health Law Studies	Saint Louis University School of Law, Saint Louis, MO
2022	Adjunct Faculty	Beazley Institute for Health Law and Policy	Loyola University Chicago School of Law, Chicago, IL
2020-2022	Lecturer	Health Sciences / Public Health	California State University East Bay, Hayward, CA
2020-2021	Teaching Faculty	Center for Bioethics	Harvard Medical School, Boston, MA
2019-2021	Adjunct Faculty	Health Law and Intellectual Property	Northeastern University School of Law, Boston, MA
2019-2021	Visiting Scholar	Center for Health Policy and Law	Northeastern University School of Law, Boston, MA
2018-2021	Research Fellow	Regulatory Science	Harvard Medical School, Boston, MA
2016-2018	Research Fellow	Pharmaceutical Law and Health Services Research	Harvard Medical School, Boston, MA

9. *Expansion of the Priority Review Voucher Program under the 21st Century Cures Act: Implications for Innovation and Public Health* (with Nina Jain, Thomas J. Hwang & Aaron S. Kesselheim), 44 AM. J. L. & MED. 329 (2018). (symposium)
Cited by the Government Accountability Office (January 2020, GAO-20-251) and in testimony to the U.S. House Committee on Energy and Commerce (July 2020).
10. *When Markets Fail: Patents and Infectious Disease Products* (with Jonathan J. Darrow & Aaron S. Kesselheim), 73 FOOD & DRUG L. J. 361 (2018).
Discussed in RAPS REGULATORY FOCUS article
11. *The Opioid Epidemic: Fixing a Broken Pharmaceutical Market* (with Ameet Sarpatwari & Aaron S. Kesselheim), 11 HARV. L. & POL'Y REV. 463 (2017).
12. *The Perils of Panic Ebola, HIV, and the Intersection of Global Health and Law* (with Wendy E. Parmet), 42 AM. J. L. & MED. 223 (2016) (symposium)
13. *Barking Up the Wrong Tree: The FDA's Misguided Attempt to Waive Informed Consent in Public Health Emergencies*, 28 J. LEGAL MED. 397 (2007). (student comment)
Nominated for the Scribes Law Review Award

Federal Comments

1. *COVID-19 Emergency Temporary Standard Rulemaking; Occupational Safety and Health Administration* (with David Michaels, Peg Seminario, and more than 100 cosigned experts in occupational safety and health, medicine, epidemiology, industrial hygiene, aerosol science, public health law and other relevant fields), April 22, 2022, <https://www.regulations.gov/comment/OSHA-2020-0004-2033>.
2. *Phased Approach to the Resumption of Cruise Ship Passenger Operations 2021-09094* (revised and contributed to 20 law student submissions as part of the Summer 2021 Problems in Public Health Law course at NUSL), June 30, 2021, <https://www.regulations.gov/document/CDC-2021-0011-0001>.
3. *Listing of Patent Information in the Orange Book; Establishment of a Public Docket; Request for Comments; Reopening of Comment Period* (with Reed F. Beall), April 15, 2021, <https://www.regulations.gov/comment/FDA-2020-N-1127-0028>.
4. *National Institute of Standards and Technology (NIST) Request for Comments; Rights to Federally Funded Inventions and Licensing of Government Owned Inventions*, April 6, 2021, <https://www.regulations.gov/comment/NIST-2021-0001-15844>.
5. *Treatment of E-Cigarettes in the Mail* (revised and contributed to 10 law student submissions as part of the Spring 2021 Problems in Public Health Law course at NUSL), March 22, 2021, <https://www.regulations.gov/document/USPS-2021-0027-0001>.
6. *FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic; Guidance for Industry, Investigators, and Institutional Review Boards* (with Deborah Plana & Andrea Arfé), July 13, 2020, <https://www.regulations.gov/document?D=FDA-2020-D-1106-0139>.
7. *Tobacco Products; Required Warnings for Cigarette Packages and Advertisements* (revised and contributed to 7 law student submissions as part of the Fall 2019 Drug Law & Policy course at NUSL), November 27, 2019, <https://www.regulations.gov/document/FDA-2019-N-3065-0001>.
8. *FDA Solicits Input on Potential Role for Abuse-Deterrent Formulations of Central Nervous System Stimulants; Establishment of a Public Docket; Request for Comments*, November 18, 2019, <https://www.regulations.gov/document?D=FDA-2019-N-3403-0886>.
9. *Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction; Public Hearing*, November 18, 2019, <https://www.regulations.gov/document?D=FDA-2019-N-2514-0396>.
10. *Comments on Public Meeting: Responsible Innovation in Dietary Supplements*, July 17, 2019, <https://www.regulations.gov/document?D=FDA-2019-N-1388-0064>.

11. (with Public Health Law Watch), December 7, 2018, <https://www.regulations.gov/docket?D=USCIS-2010-0012>.
12. *A Response to "Unintended Consequences: Medicaid and the Opioid Crisis"* (with Public Health Law Watch), February 14, 2018, <https://www.publichealthlawwatch.org/blog/2018/2/14/a-response-to-unintended-consequences-medicare-and-the-opioid-crisis>.
13. -*Waxman Amendments: Ensuring a* (with Ameet Sarpatwari & Aaron Kesselheim), Nov 10, 2017, <https://www.regulations.gov/document?D=FDA-2017-N-3615-0092>.
14. (with Aaron S. Kesselheim), Jun 2, 2017, <https://www.regulations.gov/document?D=FDA-2013-N-0402-0034>.

Book Chapters

1. *Addressing Regulatory Exclusivity Issues During the COVID-19 Pandemic* (with Sven J.R. Bostyn & Timo Minssen), in *COVID-19 AND THE LAW: DISRUPTION, IMPACT, AND LEGACY* (I. Glenn Cohen, Abbe D. Gluck, Katherine Kraschel & Carmel Shachar, eds.) (forthcoming 2022). Available on SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3889894.
2. *Identifying and Eradicating Gender Discrimination and Sexual Harassment of Women Physicians in the United States* (with Christine A. Heisler, Melissa Blaker, Elizabeth H. Stephens, Kate Walsh, Pringl Miller & Sarah M. Temkin), in *GLOBAL PERSPECTIVES ON SEXUAL HARASSMENT IN MEDICINE* (Louise Stone, ed.) (forthcoming 2022)
3. *Strategies to Address the Chronic Shortage of N95 Masks and Other Filtering Facepiece Respirators During the COVID-19 Pandemic*, in *COVID-19 POLICY PLAYBOOK: LEGAL*

15. *Brief in Support of Appellant by Amici Curiae the Health in Justice Action Lab at Northeastern University School of Law and the Center for Public Health Research at Temple University School*

7. *Fentanyl panic goes viral: The spread of misinformation about overdose risk from casual contact with fentanyl in mainstream and social media* (with Leo Beletsky, Sarah Seymour, Sunyou Kang, Zachary Siegel, Ryan Marino, Aashka Dave & Clark Freifeld). 16 INT'L. J. DRUG POL'Y. 102951 (2020).

Discussed in MIAMI HERALD, VICE, PHILADELPHIA INQUIRER, NEW YORK TIMES, LOS ANGELES TIMES, and ABC NEWS articles

20. *The Impact of Tort Reform and*

Non-Peer Reviewed Scientific or Medical Publications

Op-eds and Blogs

1. *Letter from Legal and Public Health Experts to Senator Elizabeth Warren*, April 20, 2022, <https://www.warren.senate.gov/imo/media/doc/2022.4.20%20Letter%20to%20Warren%20on%20Drug%20Pricing%20Executive%20Authorities.pdf>.
2. *Patient advocacy organizations and FDA drug approval: Lessons from aducanumab* (with Stephen Latham), STAT NEWS FIRST OPINION, July 23, 2021, <https://www.statnews.com/2021/07/23/patient-advocacy-organizations-lessons-from-aducanumab/>.
3. *Open Letter to FDA Commissioner Stephen Hahn: #ProtectTheFDA*, September 25, 2020, <http://bit.ly/ProtectTheFDA>.
4. *Letter in Support of Dr. Anthony Fauci and His Role in the U.S. COVID-19 Response*, July 17, 2020, <https://cspinet.org/resource/letter-support-dr-anthony-fauci-and-his-role-us-covid-19-response>.
5. *Re-Envisioning Clinical Trials During the COVID-19 Pandemic* (with Deborah Plana and Andrea Arfé), HEALTH AFFAIRS BLOG, July 8, 2020, <https://www.healthaffairs.org/doi/10.1377/hblog20200702.963588/full/>.
6. *Letter to Congress on WHO Withdrawal from Public Health, Law and International Relations Leaders*, June 30, 2020, <https://oneill.law.georgetown.edu/letter-to-congress-on-who-withdrawal-from-public-health-law-and-international-relations-leaders/>.
7. *Letter to Icelandic Minister of Health, Surgeon General, and Chief Epidemiologist: Antibody assay for COVID-19, some legal and ethical issues* (with Hrefna D. Gunnarsdottir), April 17, 2020.
8. *Opinion: Why we should be wary of an aggressive government response to coronavirus* (with Wendy E. Parmet). THE WASHINGTON POST. February 3, 2020, <https://www.washingtonpost.com/outlook/2020/02/03/why-we-should-be-wary-an-aggressive-government-response-coronavirus/>.
9. (with Shaleen Title), THE PHILADELPHIA INQUIRER, October 7, 2019, <https://www.inquirer.com/opinion/commentary/vaping-ban-massachusetts-new-jersey-pennsylvania-deaths-20191007.html>.
10. *Overwhelming Support for Gender Equity at the AMA* (with Julie K. Silver), DOXIMITY OP-(M)ED, June 14, 2018, <https://opmed.doximity.com/overwhelming-support-for-gender-equity-at-the-ama-526ea22bfb8c>.
11. *The Future of American Science and Medicine* (with Aaron S. Kesselheim), THE SPOKE (blog of the Albright Institute Faculty Scholar Initiative, Wellesley College), July 25, 2017, <https://www.wellesley.edu/albright/about/blog/3516-future-american-science-and-medicine>.
12. *Le* THE NEW YORK TIMES. June 23, 2017, <https://www.nytimes.com/2017/06/23/opinion/professors-call-health-bills-a-giant-step-backward.html>.
13. *The Current 21st Century Cures Legislation Is Still A Bad Deal For Patients* (with Ameet Sarpatwari), HEALTH AFFAIRS BLOG, November 30, 2016, <http://healthaffairs.org/blog/2016/11/30/the-current-21st>

Newsletters

1. *Monthly Round-Up of What to Read on Pharma Law and Policy* (with Ameet Sarpatwari & Aaron S. Kesselheim), PORTAL LITERATURE SCAN (Program On Regulation, Therapeutics, And Law, Boston, MA), June 2017 ó October 2018, <https://www.portalresearch.org/literature-scan.html>.
2. *The Massachusetts Health Insurance Program*, SANGAMON MEDICAL NEWS (Sangamon County Medical Society, Springfield, IL), 2010
3. ACLM Student Editorial Board. LEGAL MEDICINE PERSPECTIVES. (American College of Legal Medicine, Schaumburg, IL), Issues 15(5) ó16(3), 2006-2007.
4. *All the latest developments in health care law* (with W. Eugene Basanta & Andrew Roszak) HEALTH CARE LAWYER (Illinois State Bar Association, Springfield, IL), Issues 23(1) ó 24(1), 2006-2007.

Abstracts

1. *Medication Use and Spending Among Adults with Diabetes: Comparing Marketplace and Medicaid Plans* (with Peggah Khorrami, Aditi Bhanja, Heidi L. Allen, Aaron S. Kesselheim & Benjamin D. Sommers), AcademyHealth Annual Research Meeting, June 2021.
2. *#MeToo is Reshaping Medicine – How Will the System Adapt?* (with Sarah J. Diekman), presented at the ACLM 59th Annual Meeting, February 2019, Los Angeles, CA. Published: 41 J. L. MED. 6 (Supp. 1 2020).
3. *The Impact of Tort Reform and Quality Improvements on Medical Liability Claims: A Tale of 2 States* (with Kenneth D. Illingworth, Steven H. Shaha, Tony H. Tzeng & Khaled J. Saleh), presented at the American Academy of Orthopedic Surgery Annual Meeting, March 2013, Chicago, IL.
4. *Medical and Law Students* (with Sameer S. Vohra, W. Eugene Basanta & Kristina Dzara), presented at the Association of American Medical Colleges Annual Meeting, Student Programming Showcase, November 2010, Washington, DC.

Theses

1. *Synthesis of Novel Anti-tumor Alkaloids* (2003) (unpublished undergraduate honors thesis, Dartmouth College) (on file with the Dartmouth College Department of Chemistry).
2. *Improving Healthcare Transitions for Releases from Boston-Area Jails* (2015) (unpublished practicum project, Harvard T.H. Chan School of Public Health) (on file with the Harvard T.H. Chan School of Public Health, Department of Health Policy and Management).